Some studied showed that increased expression of ARID1B forebodes poor survival in triple-negative breast cancer patients [15], while, another one reported ARID1B potentially served as a valuable prognostic indicator and therapeutic target in breast cancer patients with triple-negative subtypes [16]. Here, ARID1B is linked to triple-negative breast carcinoma.